Amir Darki, MD
Interventional Cardiology · Maywood, ILNPI 1285835413
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 35.1% of the total. Reporting peaked in 2022 at $5,438 and has fallen 76.6% since, to $1,274 in 2025.
Across 143 payments — averaging $117.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Inari Medical, Inc.$3K
- Sanofi-aventis U.S. LLC$3K
- Boston Scientific$2K
- Medtronic$1K
- Angiodynamics, Inc.$351
- plus $2K from 15 others
Across 20 payments — averaging $4267.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$54K
- Penumbra, Inc.$31K
What the payments were for
- Consulting fees$3,97024%
- Speaking & faculty fees$4,20025%
- Travel & lodging$2,88617%
- Food & beverage$5,72334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $5,894 |
| Inari Medical, Inc. | 34 | $2,955 |
| Sanofi-aventis U.S. LLC | 1 | $2,720 |
| Boston Scientific | 34 | $2,273 |
| Medtronic | 14 | $1,001 |
| Angiodynamics, Inc. | 2 | $351 |
| Cardiovascular Systems Inc. | 5 | $299 |
| Stryker | 11 | $263 |
| Penumbra, Inc. | 2 | $232 |
| Abiomed | 2 | $230 |
| Terumo Medical Corporation | 1 | $160 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $138 |
| Edwards Lifesciences | 2 | $46 |
| Atricure, Inc. | 1 | $32 |
| Shockwave Medical, Inc | 1 | $32 |
| Microvention, Inc. | 1 | $29 |
| Amgen | 1 | $27 |
| W. L. Gore & Associates, Inc. | 2 | $27 |
| Surmodics, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| United Therapeutics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$2,888
- MULTAQ$2,720
- FLOWTRIEVER CATHETER, S$1,392
- CT THROMBECTOMY SYSTEM KIT$1,392
- AMPLATZER PICCOLO$1,313
- Ultreon$1,250
- FlowTriever$972
- ClotTriever$972
- STINGRAY$893
- RESOLUTE ONYX$728
- GENERAL VASCULAR ACCESS$458
- AlphaVac$299
- Impella$230
- Diamondback Peripheral$182
- Diamondback Coronary$182
- METACROSS OTW$160
- GlideWire$160
- Heartrail$160
- GLIDESHEATH SLENDER$160
- RUBY Coil$144
How this compares
$16,779 in reported general payments places this provider in the 70th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 406 | $424,215 |
| Repatha SureclickEvolocumab | 125 | $135,380 |
| EntrestoSacubitril/Valsartan | 136 | $133,265 |
| XareltoRivaroxaban | 86 | $111,379 |
| BrilintaTicagrelor | 33 | $36,376 |
| MultaqDronedarone Hcl | 17 | $30,731 |
| JardianceEmpagliflozin | 25 | $26,893 |
| FarxigaDapagliflozin Propanediol | 26 | $23,882 |
| Praluent PenAlirocumab | 18 | $21,170 |
| Atorvastatin Calcium | 711 | $7,470 |
| Metoprolol Succinate | 500 | $7,364 |
| Ezetimibe | 235 | $5,425 |
| ClopidogrelClopidogrel Bisulfate | 407 | $4,874 |
| Prasugrel Hcl | 69 | $3,828 |
| Ranolazine ErRanolazine | 46 | $3,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCMultaq | $2,720 | $30,73117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Maywood
- Bruce LewisMaywood$83K
- Demetrios DoukasMaywood$31K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.